Healthia Limited
Healthia Limited Fundamental Analysis
Healthia Limited (HLA.AX) shows weak financial fundamentals with a PE ratio of 39.05, profit margin of 2.48%, and ROE of 4.32%. The company generates $0.2B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 23.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze HLA.AX's fundamental strength across five key dimensions:
Efficiency Score
WeakHLA.AX struggles to generate sufficient returns from assets.
Valuation Score
ModerateHLA.AX shows balanced valuation metrics.
Growth Score
ModerateHLA.AX shows steady but slowing expansion.
Financial Health Score
WeakHLA.AX carries high financial risk with limited liquidity.
Profitability Score
WeakHLA.AX struggles to sustain strong margins.
Key Financial Metrics
Is HLA.AX Expensive or Cheap?
P/E Ratio
HLA.AX trades at 39.05 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, HLA.AX's PEG of 0.39 indicates potential undervaluation.
Price to Book
The market values Healthia Limited at 1.59 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 0.26 times EBITDA. This is generally considered low.
How Well Does HLA.AX Make Money?
Net Profit Margin
For every $100 in sales, Healthia Limited keeps $2.48 as profit after all expenses.
Operating Margin
Core operations generate 11.38 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $4.32 in profit for every $100 of shareholder equity.
ROA
Healthia Limited generates $1.58 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Healthia Limited generates limited operating cash flow of $16.06M, signaling weaker underlying cash strength.
Free Cash Flow
Healthia Limited produces free cash flow of $11.41M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.12 in free cash annually.
FCF Yield
HLA.AX converts 9.23% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
39.05
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.39
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.59
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.69
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.09
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.72
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.04
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.08
vs 25 benchmark
How HLA.AX Stacks Against Its Sector Peers
| Metric | HLA.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 39.05 | 27.91 | Worse (Expensive) |
| ROE | 4.32% | 687.00% | Weak |
| Net Margin | 2.48% | -45285.00% (disorted) | Weak |
| Debt/Equity | 1.09 | 0.33 | Weak (High Leverage) |
| Current Ratio | 0.72 | 2795.76 | Weak Liquidity |
| ROA | 1.58% | -13557.00% (disorted) | Weak |
HLA.AX outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Healthia Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation